<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-2-5-1">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>			
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>	
			</div>

			<div class="slide-title red">
				The patient journey: from moderate to severe aplastic anaemia
			</div>


			<div class="content-container">

				<img class="center-img" src="media/images/slide_2-5-1/picture1.png" alt="">

			</div>

		</div>

		<div class="information-overlay overlay" style="font-size:12px">
			
			<header>The patient journey: from moderate to severe aplastic anaemia</header>
			
			<ul>
				<li><span>Aplastic anaemia is a rare but heterogeneous disorder characterised by bone marrow failure<sup>2</sup></span>
					<ul>
						<li><span>The disorder may be inherited or acquired<sup>3</sup></span></li>
						<li><span>In 15–20% of cases, aplastic anaemia is the result of an inherited genetic disorder<sup>3</sup></span>
							<ul>
								<li><span>~70% of acquired aplastic anaemia cases: idiopathic because the primary cause has not been elucidated<sup>3</sup></span></li>
								<li><span>10–15% of cases: secondary to an identifiable factor<sup>3</sup></span></li>
							</ul>
						</li>
					</ul>
				</li>
				<li><span>Disease severity is classified according to blood count thresholds and bone marrow findings as moderate (non-severe), severe and very severe<sup>2</sup></span></li>
				<li><span>Non-severe (moderate) aplastic anaemia:</span>
					<ul>
						<li><span>Variable clinical course, but seldom life-threatening<sup>4</sup></span></li>
						<li><span>Patients may have moderate cytopenia but are asymptomatic<sup>5</sup></span></li>
						<li><span>Moderate aplastic anaemia may not require treatment (‘watch and wait’)<sup>6</sup></span></li>
						<li><span>Patients commonly seek medical attention and a diagnosis when they experience symptoms of anaemia or bleeding, by which time pancytopenia and haematopoietic stem cell deficiency has worsened<sup>6</sup></span></li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Brodsky RA & Jones RJ. <i>Lancet</i> 2005;365:1647</span></li>
				<li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Marsh JCW <i>et al. Br J Haematol</i> 2009;147:43</span></li>
				<li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Dokal I & Vulliamy T. Blood <i>Reviews</i> 2008;22:141</span></li>
				<li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>DeZern AE & Brodsky RA. <i>Exp Rev Hematol</i> 2011;4:221</span></li>
				<li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Bacigalupo A & Passweg J <i>et al. Haematol Oncol Clin N Am</i> 2009;23:159</span></li>
				<li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Scheinberg P & Young NS. <i>Blood</i> 2012;120:1185</span></li>
			</ol>

		</div>

	</div>
</div>